DE69838647D1 - Behandlung von fettleibigkeit - Google Patents

Behandlung von fettleibigkeit

Info

Publication number
DE69838647D1
DE69838647D1 DE69838647T DE69838647T DE69838647D1 DE 69838647 D1 DE69838647 D1 DE 69838647D1 DE 69838647 T DE69838647 T DE 69838647T DE 69838647 T DE69838647 T DE 69838647T DE 69838647 D1 DE69838647 D1 DE 69838647D1
Authority
DE
Germany
Prior art keywords
treatment
obesity
analogue
carboxyl
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69838647T
Other languages
English (en)
Other versions
DE69838647T2 (de
Inventor
Frank Man-Woon Ng
Woei-Jia Jiang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabolic Pharmaceuticals Pty Ltd
Original Assignee
Metabolic Pharmaceuticals Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO9001A external-priority patent/AUPO900197A0/en
Priority claimed from AUPP0398A external-priority patent/AUPP039897A0/en
Application filed by Metabolic Pharmaceuticals Pty Ltd filed Critical Metabolic Pharmaceuticals Pty Ltd
Publication of DE69838647D1 publication Critical patent/DE69838647D1/de
Application granted granted Critical
Publication of DE69838647T2 publication Critical patent/DE69838647T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Reverberation, Karaoke And Other Acoustics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Photolithography (AREA)
DE69838647T 1997-09-08 1998-09-04 Behandlung von fettleibigkeit Expired - Lifetime DE69838647T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPO900197 1997-09-08
AUPO9001A AUPO900197A0 (en) 1997-09-08 1997-09-08 Treatment of obesity
AUPP0398A AUPP039897A0 (en) 1997-11-13 1997-11-13 Treatment of obesity
AUPP039897 1997-11-13
PCT/AU1998/000724 WO1999012969A1 (en) 1997-09-08 1998-09-04 Treatment of obesity

Publications (2)

Publication Number Publication Date
DE69838647D1 true DE69838647D1 (de) 2007-12-13
DE69838647T2 DE69838647T2 (de) 2008-08-28

Family

ID=25645599

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69838647T Expired - Lifetime DE69838647T2 (de) 1997-09-08 1998-09-04 Behandlung von fettleibigkeit

Country Status (12)

Country Link
US (2) US6737407B1 (de)
EP (1) EP1012189B1 (de)
JP (1) JP4334761B2 (de)
CN (1) CN1195776C (de)
AT (1) ATE377026T1 (de)
BR (1) BR9811755A (de)
CA (1) CA2303395C (de)
DE (1) DE69838647T2 (de)
ES (1) ES2296342T3 (de)
NZ (1) NZ502993A (de)
RU (1) RU2223970C2 (de)
WO (1) WO1999012969A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ387599A0 (en) 1999-11-05 1999-12-02 Metabolic Pharmaceuticals Limited Product and method for control of obesity
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
ES2343518T3 (es) * 2002-09-09 2010-08-03 Hanall Biopharma Co., Ltd. Polipeptidos interferon alfa modificados resistentes a proteasas.
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
GB0315182D0 (en) * 2003-06-28 2003-08-06 Asterion Ltd Cytokine variant polypeptides
WO2005007859A2 (en) * 2003-07-11 2005-01-27 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF ACETYL-COA CARBOXYLASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2005105132A1 (en) * 2004-05-04 2005-11-10 Metabolic Pharmaceuticals Limited Methods for preventing or treating bone disorders
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
ES2258923B1 (es) * 2005-02-23 2007-11-01 Universitat De Les Illes Balears Uso de la leptina para la prevencion del exceso de peso corporal y composicion que contiene leptina.
US20110092448A1 (en) * 2005-08-02 2011-04-21 Metabolic Pharmaceuticals Limited Peptide Conjugate for Oral Delivery of Hydrophilic Peptide Analgesics
WO2007068039A1 (en) * 2005-12-12 2007-06-21 Metabolic Pharmaceuticals Limited Treatment of weight gain in estrogen deficient mammals
EP2644618B1 (de) 2007-02-09 2016-08-17 Ocera Therapeutics, Inc. Intermediaten für die Synthese von Makrozyklische Ghrelin-Rezeptormodulatoren
WO2008098280A1 (en) * 2007-02-16 2008-08-21 Polychip Pharmaceuticals Pty Ltd Methods for the synthesis of dicarba bridges in growth hormone peptides
WO2010033207A1 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of therapeutic peptides
US20110237524A1 (en) * 2008-09-19 2011-09-29 Nektar Therapeutics Polymer conjugates of aod-like peptides
KR20140101397A (ko) 2011-12-09 2014-08-19 메타볼릭 파마슈티칼즈 피티와이 엘티디 성장 호르몬 단편들의 사용
CN102827290A (zh) * 2012-09-07 2012-12-19 浙江大学 人血清白蛋白与人生长激素脂肪分解结构域的融合蛋白
GB2507341A (en) * 2012-10-29 2014-04-30 Peter Kenny Fat loss composition comprising a prostaglandin F2 alpha analogue and a fragment of amino acids 176-191 of human growth hormone
CA3088014A1 (en) * 2018-01-15 2019-07-18 Lateral IP Pty Ltd Human growth hormone-derived peptides, and non-human variants thereof, for treating neuropathic pain

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG49718A3 (en) 1983-07-15 1992-01-15 Bio- Technology General Corp Method for preparing of polypeptid with superoxiddismutasne activitty
US4863901A (en) 1986-01-09 1989-09-05 Brigham & Women's Hospital Use of growth hormone for nitrogen retention under hypocaloric conditions
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
AU693478B2 (en) * 1994-11-10 1998-07-02 Metabolic Pharmaceuticals Limited Treatment of obesity

Also Published As

Publication number Publication date
ES2296342T3 (es) 2008-04-16
EP1012189A4 (de) 2004-10-20
CN1275132A (zh) 2000-11-29
CA2303395C (en) 2008-12-02
US6737407B1 (en) 2004-05-18
CA2303395A1 (en) 1999-03-18
CN1195776C (zh) 2005-04-06
JP4334761B2 (ja) 2009-09-30
BR9811755A (pt) 2000-08-29
ATE377026T1 (de) 2007-11-15
NZ502993A (en) 2002-12-20
EP1012189A1 (de) 2000-06-28
DE69838647T2 (de) 2008-08-28
WO1999012969A1 (en) 1999-03-18
RU2223970C2 (ru) 2004-02-20
JP2002501004A (ja) 2002-01-15
EP1012189B1 (de) 2007-10-31
US20040192608A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
DE69838647D1 (de) Behandlung von fettleibigkeit
HUP0004560A2 (hu) Törést gyógyító PTHrP analógok
MX9703643A (es) Metodos para tratamiento de esclerosis multiple usando analogos de peptidos de proteina basica de mielina humana.
IL109403A0 (en) Oral drug delivery compositions and methods
EE9700244A (et) Prootonpumba inhibiitorit sisaldav farmatseutiline kompositsioon
HUP0100928A2 (hu) Humán inzulin B láncának részletét tartalmazó peptidanalógok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
HUP0003349A2 (hu) Mellékpajzsmirigy-hormon peptidanalógok, ezeket hatóanyagként tartalmazó gyógyászati készítmények és alkalmazásuk
DE69931793D1 (de) Verfahren für die behandlung der multiplen sklerose mittels peptidanalogen des menschlichen basischen myelinproteins
ATE213499T1 (de) Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose
DE3483931D1 (de) Wachstumshormone freisetzende peptiden und methode fuer die behandlung von saeugetieren.
HUP0401441A2 (hu) Az 5-CNAC mint mellékpajzsmirigy hormon fragmentumok orális hordozószere
DE69131355D1 (de) Die knochenresorption hemmende verbindungen und zusammensetzungen
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
DE69816808D1 (de) Somatostatin agoniste zur reduzierung von körpergewicht
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
KR920700224A (ko) 신규의 생리활성 펩티드 및 이를 유효성분으로서 함유한 칼슘대사 조절제
ATE218869T1 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen
DE60028682D1 (de) Wachstumhormone Inhibitoren Enthaltende pharmazeutische Zubereitungen oder ihre biologisch aktive Fragmente zur Behandlung von uterinen Myomas
MX9700199A (es) Composiciones de cadena invariante utiles para tratar enfermedades autoinmunes.
MX9604539A (es) Aminoacidos modificados para la distribucion de farmaco.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition